Skip to content

Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery

Addition of Dexmedetomidine to Ropivacaine for Ultrasound Guided Erector Spinae Block: Evaluation of Effect on Postoperative Pain After Breast Surgery: A Double-Blinded, Prospective, Randomized Clinical Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04029467
Enrollment
44
Registered
2019-07-23
Start date
2019-07-17
Completion date
2022-01-17
Last updated
2021-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Axillary Lymph Node Dissection, Breast Cancer, Mastectomy, Pain, Postoperative

Keywords

ESP block, erector spinae plane block, mastectomy, ropivacaine, dexmedetomidine, pain, breast

Brief summary

Patients undergoing Partial or total mastectomy with axillary LN dissection will receive prior to induction of general anaesthesia ESP block at T4 level at the same side of the surgery. one group will receive ropivacaine 0.375% and the other will get ropivacaine 0.375% with dexmedetomidine 0.5mcg/kg as an adjuvant. time to first narcotic requirement will be documented and therefore an assessment of the duration of action of the block will be made

Detailed description

Background and Objective: Whether partial or complete, mastectomy with axillary lymph node dissection is a painful surgery. Acute postoperative pain management is challenging and crucial due to high chances of it transforming into chronic pain. Erector spinae plane (ESP) block has been shown to be effective in managing post mastectomy pain.Dai et al showed the effectiveness of dexmedetomidine in prolonging the duration of sensory block, motor block and analgesia when dexmedetomidine as an adjunct is added to ropivacaine in brachial plexus block (1). The aim of our study is to show the effectiveness of dexmedetomidine in prolonging the analgesic effect of ropivacaine when added to it in ESP block compared to using ropivacaine alone in patients undergoing mastectomy with axillary lymph node dissection, and to study its impact on postoperative opioid consumption. Methods: 44 American Society of Anesthesiologist (ASA) physical status classification class I, II and III will be randomly allocated to one of two groups, both receiving a single injection erector spinae plane block at T4 vertebral level using 20ml ropivacaine 0.375% 20 minutes before the induction of anesthesia. The first group will receive 0.5mcg/kg of dexmedetomdine added to the ropivacaine solution. The control group will receive no dexmedetomidine. Postoperatively, patients in both groups will be receive acetaminophen 1g orally every 6 hours and oxycodone 5 mg orally as needed every 6 hours if VAS is more than 4. Postoperative pain will be measured using Verbal Analogue Scale (VAS) at 0, 1, 2, 4, 6, 12, 18, and 24 hours. Conclusion: This study will be the first of its kind to investigate the impact of adding dexmedetomidine as an adjunct to ropivacaine in prolonging the ESP block duration in patients undergoing mastectomy with axillary lymph node dissection.

Interventions

DRUGDexmedetomidine

addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action

Sponsors

Lebanese American University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. ASA class I, II and III patients 2. Age range: 18-80 years old 3. Elective partial or unilateral radical mastectomy with sentinel lymph node dissection

Exclusion criteria

1. Pregnant woman 2. Bilateral mastectomy. 3. Skin infection at the site of needle puncture 4. Coagulopathy problems 5. Allergy or contraindication to any of the study drugs 6. Recent use of opioid drugs

Design outcomes

Primary

MeasureTime frameDescription
Pain assessment in the first 24 hours post operatively: VAS score24 hoursPain will be assessed using the VAS score ranging from 0, indicating no pain at all, to 10, indicating the worst pain the patient has ever felt

Countries

Lebanon

Contacts

Primary ContactYara Al Jalbout, MD
yara.aljalbout@lau.edu.lb+9611200800
Backup ContactHanane Barakat, MD
hanane.barakat@laumcrh.com+9611200800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026